JP2019515927A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515927A5
JP2019515927A5 JP2018556356A JP2018556356A JP2019515927A5 JP 2019515927 A5 JP2019515927 A5 JP 2019515927A5 JP 2018556356 A JP2018556356 A JP 2018556356A JP 2018556356 A JP2018556356 A JP 2018556356A JP 2019515927 A5 JP2019515927 A5 JP 2019515927A5
Authority
JP
Japan
Prior art keywords
infection
pharmaceutical composition
composition according
subject
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030236 external-priority patent/WO2017190070A1/en
Publication of JP2019515927A publication Critical patent/JP2019515927A/ja
Publication of JP2019515927A5 publication Critical patent/JP2019515927A5/ja
Pending legal-status Critical Current

Links

JP2018556356A 2016-04-29 2017-04-28 感染症の処置のための方法 Pending JP2019515927A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662329514P 2016-04-29 2016-04-29
US62/329,514 2016-04-29
US201662400503P 2016-09-27 2016-09-27
US62/400,503 2016-09-27
US201762470419P 2017-03-13 2017-03-13
US62/470,419 2017-03-13
PCT/US2017/030236 WO2017190070A1 (en) 2016-04-29 2017-04-28 Methods for the treatment of infection

Publications (2)

Publication Number Publication Date
JP2019515927A JP2019515927A (ja) 2019-06-13
JP2019515927A5 true JP2019515927A5 (https=) 2020-06-18

Family

ID=60161141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556356A Pending JP2019515927A (ja) 2016-04-29 2017-04-28 感染症の処置のための方法

Country Status (7)

Country Link
US (2) US20190133995A1 (https=)
EP (1) EP3448377A4 (https=)
JP (1) JP2019515927A (https=)
CN (1) CN109715152A (https=)
AU (1) AU2017258765A1 (https=)
CA (1) CA3022391A1 (https=)
WO (1) WO2017190070A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2019240212A1 (ja) * 2018-06-14 2021-06-24 株式会社カネカ 薬学的活性成分を含む製剤
WO2022204014A1 (en) * 2021-03-25 2022-09-29 Per Os Biosciences, Llc. Compositions and methods for treating coronavirus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CN1939917A (zh) * 1999-03-22 2007-04-04 免疫力药品有限公司 大麻酯衍生物及其药用
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) * 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
AU2003303376A1 (en) * 2002-12-19 2004-07-22 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
PT1903866E (pt) * 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US9192598B2 (en) * 2008-06-25 2015-11-24 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
KR20190139327A (ko) * 2013-02-12 2019-12-17 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
US20150328198A1 (en) * 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Similar Documents

Publication Publication Date Title
Blanchette et al. Current therapies in treatment and prevention of fracture wound biofilms: why a multifaceted approach is essential for resolving persistent infections
JP2013542999A5 (https=)
EP2849777B1 (en) Seaprose for removing bacterial biofilm
US20140371179A1 (en) Methods and Compositions for Treating Esophageal Diseases
JP2020524689A5 (https=)
UA124661C2 (uk) Композиція, що містить антибіотик та диспергатор або антиадгезивний агент
WO2001005400A1 (en) Nitroimidazole external preparations for dermatosis
US20220211801A1 (en) Compositions and methods for treating nail infections
AU2020232773B2 (en) Percutaneous anti-microbiota formulations
JP7418475B2 (ja) バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用
JP2019515927A5 (https=)
EP2440216A1 (en) Use of a composition for the treatment of mucositis
EP3148555A1 (en) Gold (i)-phosphine compounds as anti-bacterial agents
US20250090527A1 (en) Wound treatments and compounds
US20140348787A1 (en) Methods and Compositions for Treating Ear Infections
JP2025515314A (ja) 緩衝剤を含有する組成物及びその使用方法
EP3419628B1 (en) Medicament for treatment of diabetic foot infections
WO2021202990A2 (en) Methods for the treatment of betacoronavirus infections
US9763934B2 (en) Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
AU2017258765A1 (en) Methods for the treatment of infection
US20250108027A1 (en) Topical delivery of edta compositions
EP2203152A1 (en) Mouthwash and method of using same for the treatment of mucositis or stomatitis
US20240100004A9 (en) Topical compositions and methods of formulating same
Frank et al. Physical Incompatibility of Antibiotics and Antimycotics in Infusion Solutions
EP1767199A2 (en) Methods and compositions for treatment of cancer pain